Artiva Biotherapeutics

Artiva Biotherapeutics company information, Employees & Contact Information

Artiva Biotherapeutics is an immunotherapy company with the ability to produce off-the-shelf, allogeneic NK cell therapies at a massive scale. Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our lead program, AlloNK®, is an allogeneic, non-genetically modified NK cell therapy candidate designed to enhance the activity of monoclonal antibodies or NK cell engagers. AlloNK is currently in clinical trials in combination with rituximab for treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis and for treatment of Non-Hodgkin Lymphoma, as well as in combination with Affimed’s innate cell engager AFM13 for the treatment of patients with relapsed/refractory CD30-positive lymphomas.

Company Details

Employees
104
Founded
-
Address
5505 Morehouse Drive, Suite 100, San Diego,california 92121,united States
Phone
858-267-4467
Email
in****@****bio.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
San Diego, California
Looking for a particular Artiva Biotherapeutics employee's phone or email?

Artiva Biotherapeutics Questions

News

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025 - GlobeNewswire

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025 GlobeNewswire

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update - Yahoo Finance

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update Yahoo Finance

Artiva Biotherapeutics to Participate in Cantor Global Healthcare Conference 2025 - Quiver Quantitative

Artiva Biotherapeutics to Participate in Cantor Global Healthcare Conference 2025 Quiver Quantitative

Artiva Biotherapeutics Receives FDA Fast Track Designation for AlloNK® in Lupus Nephritis - Business Wire

Artiva Biotherapeutics Receives FDA Fast Track Designation for AlloNK® in Lupus Nephritis Business Wire

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting - GlobeNewswire

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting GlobeNewswire

Artiva Biotherapeutics Celebrates Official Opening of San Diego Corporate Headquarters and R&D Lab Facilities - Business Wire

Artiva Biotherapeutics Celebrates Official Opening of San Diego Corporate Headquarters and R&D Lab Facilities Business Wire

User - FinancialContent

User FinancialContent

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights GlobeNewswire

User - FinancialContent

User FinancialContent

Top Artiva Biotherapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant